-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $32

Benzinga·04/01/2026 17:35:21
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $28 to $32.